Effects of irbesartan and perindopril on forearm reactive hyperemia and inflammatory process, in normotensive patientswith coronary artery disease

International Journal of Cardiology

Volumn 124, Issue 1, 2008, Pages 127-129

  Tousoulis, Dimitris ^a   Kourtellaris, Pantelis ^a   Antoniades, Charalambos ^a   Vasiliadou, Carmen ^a   Papageorgiou, Nikos ^a   Tentolouris, Costas ^a   Siasos, Gerasimos ^a   Stefanadi, Elli ^a   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Angiotensin converting enzyme inhibitors; Angiotensin receptor blockers; Endothelium; Inflammation

Indexed keywords

IRBESARTAN; PERINDOPRIL; PLACEBO;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; FEMALE; HUMAN; HYPEREMIA; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECEPTOR BLOCKING; VASODILATATION;

ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; BLOOD FLOW VELOCITY; CORONARY DISEASE; E-SELECTIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOREARM; HUMANS; HYPEREMIA; INFLAMMATION; INFLAMMATION MEDIATORS; INTERCELLULAR ADHESION MOLECULE-1; LIPIDS; MALE; MIDDLE AGED; PERINDOPRIL; TETRAZOLES; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 38149104528     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2006.11.206     Document Type: Article

References (13)

1. Levy B.I. Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system. Circulation 109 1 (2004) 8-13
2. Schieffer B., Bunte C., Witte J., et al. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol 44 2 (2004) 362
3. Tousoulis D., Antoniades C., and Stefanadis C. Evaluating endothelial function in humans: a guide to invasive and non-invasive techniques. Heart 91 4 (2005) 553-558
4. Weir M.R., and Dzau V.J. The renin-angiotensin-aldosterone system: a specific target for hypertension management. Am J Hypertens 12 12 III (1999) 205S
5. Higashi Y., Sasaki S., Nakagawa K., et al. A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, beta-blockers and diuretic agents on reactive hyperemia in patients with essential hypertension: a multicenter study. J Am Coll Cardiol 35 2 (2000) 284
6. Yusuf S. Clinical, public health, and research implications of the Heart Outcomes Prevention Evaluation (HOPE) Study. Eur Heart J 22 2 (2001) 103-104
7. Blood Pressure Lowering Treatment Trialists C. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362 9395 (2003) 1527
8. Koh K.K., Han S.H., Chung W.-J., et al. Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension. Am J Cardiol 93 11 (2004) 1432
9. Brasier A.R., Recinos III A., and Eledrisi M.S. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 22 8 (2002) 1257-1266
10. Di Napoli M., and Papa F. Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of C-reactive protein in patients with first-ever ischemic stroke. Stroke 34 12 (2003) 2922-2929
11. Schram M.T., van Ittersum F.J., Spoelstra-de Man A., et al. Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized clinical trial. J Hum Hypertens 19 (2005) 429-437
12. O'Keefe J.H., Wetzel M., Moe R.R., Brosnahan K., and Lavie C.J. Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease?. J Am Coll Cardiol 37 1 (2001) 1
13. Dahlof B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 9311 (2002) 995-1003